---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055606"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:27:22.480593+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q1 net loss $116M; cash $1.70B; plans pivotal RMC-6236 trials in H2 2024

## Summary
- Net loss of $116.0M for Q1 2024, compared to $68.1M in Q1 2023.
- Revenue $0 (ended Sanofi collaboration); R&D expenses $118.0M (up from $68.9M).
- Cash $1.70B as of March 31, 2024; projected cash runway into 2027.
- Plans to initiate two pivotal monotherapy trials of RMC-6236 in 2L PDAC and 2L NSCLC in H2 2024.
- Reiterates FY2024 GAAP net loss guidance between $480M and $520M.

## SEC filing metadata
- accession: 0000950170-24-055606
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/0000950170-24-055606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/rvmd-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055606
- JSON: https://secwatch.observer/filing/0000950170-24-055606.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055606.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/0000950170-24-055606-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.